(FDMT) 4D Molecular Therapeutics - Ratings and Ratios
4D-150, 4D-710, 4D-175, 4D-725, 4D-310
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 88.4% |
| Value at Risk 5%th | 128% |
| Relative Tail Risk | -12.30% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.84 |
| Alpha | 33.41 |
| CAGR/Max DD | -0.25 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.455 |
| Beta | 1.261 |
| Beta Downside | 1.425 |
| Drawdowns 3y | |
|---|---|
| Max DD | 93.00% |
| Mean DD | 52.54% |
| Median DD | 52.33% |
Description: FDMT 4D Molecular Therapeutics October 29, 2025
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is a late-stage biotech focused on engineering adeno-associated virus (AAV) vectors through its proprietary Therapeutic Vector Evolution platform, operating labs in the Netherlands and the United States.
The company’s lead candidate, 4D-150, aims to treat retinal vascular diseases-including wet age-related macular degeneration (wAMD) and diabetic macular edema-by delivering a multi-year, intravitreal anti-VEGF expression system. The global anti-VEGF market is valued at roughly $10 billion and is projected to grow at a 6-7 % CAGR, making sustained-release gene-based approaches a potentially disruptive cost-controlling alternative.
Beyond 4D-150, the pipeline includes 4D-710 (early-stage cystic fibrosis), 4D-175 (preclinical geographic atrophy), 4D-725 (preclinical α1-antitrypsin deficiency lung disease), and 4D-310 (Phase 1 Fabry disease). Collectively, these programs address rare-disease indications that together represent a $30 billion addressable market for gene-therapy modalities.
Strategic collaborations with Astellas Gene Therapies, Arbor Biotechnologies, and uniQure provide both development expertise and non-dilutive funding; the company reported a cash runway of approximately $150 million as of its latest 10-Q, supporting runway through at least 2026 under current burn rates.
For a deeper, data-driven look at FDMT’s valuation dynamics and scenario analysis, you might find the free tools on ValueRay useful for extending your own research.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-209.2m TTM) > 0 and > 6% of Revenue (6% = 7200 TTM) |
| FCFTA -0.44 (>2.0%) and ΔFCFTA -24.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 229.4k% (prev 2.83m%; Δ -2.60mpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.43 (>3.0%) and CFO -183.5m > Net Income -209.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 8.42 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (56.1m) change vs 12m ago 1.03% (target <= -2.0% for YES) |
| Gross Margin -80.7k% (prev -514.4k%; Δ 433.7kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.02% (prev 0.00%; Δ 0.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -13.38 (EBITDA TTM -226.8m / Interest Expense TTM -16.9m) >= 6 (WARN >= 3) |
Altman Z'' -18.39
| (A) 0.65 = (Total Current Assets 312.4m - Total Current Liabilities 37.1m) / Total Assets 424.0m |
| (B) -1.74 = Retained Earnings (Balance) -735.7m / Total Assets 424.0m |
| warn (B) unusual magnitude: -1.74 — check mapping/units |
| (C) -0.44 = EBIT TTM -226.1m / Avg Total Assets 514.0m |
| (D) -13.36 = Book Value of Equity -735.0m / Total Liabilities 55.0m |
| Total Rating: -18.39 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.50
| 1. Piotroski 0.0pt |
| 2. FCF Yield -54.99% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.06 |
| 5. Debt/Ebitda 0.12 |
| 6. ROIC - WACC (= -50.82)% |
| 7. RoE -47.27% |
| 8. Rev. Trend -24.20% |
| 9. EPS Trend -13.55% |
What is the price of FDMT shares?
Over the past week, the price has changed by +1.81%, over one month by +1.90%, over three months by +53.52% and over the past year by +49.03%.
Is FDMT a buy, sell or hold?
- Strong Buy: 5
- Buy: 4
- Hold: 2
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the FDMT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 33.1 | 209.4% |
| Analysts Target Price | 33.1 | 209.4% |
| ValueRay Target Price | 11.2 | 4.7% |
FDMT Fundamental Data Overview November 25, 2025
P/S = 5161.202
P/B = 1.6785
Beta = 2.951
Revenue TTM = 120.0k USD
EBIT TTM = -226.1m USD
EBITDA TTM = -226.8m USD
Long Term Debt = 22.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.70m USD (from shortTermDebt, last quarter)
Debt = 22.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -26.3m USD (from netDebt column, last quarter)
Enterprise Value = 336.5m USD (619.3m + Debt 22.3m - CCE 305.1m)
Interest Coverage Ratio = -13.38 (Ebit TTM -226.1m / Interest Expense TTM -16.9m)
FCF Yield = -54.99% (FCF TTM -185.1m / Enterprise Value 336.5m)
FCF Margin = -154.2k% (FCF TTM -185.1m / Revenue TTM 120.0k)
Net Margin = -174.3k% (Net Income TTM -209.2m / Revenue TTM 120.0k)
Gross Margin = -9999 % ((Revenue TTM 120.0k - Cost of Revenue TTM 97.0m) / Revenue TTM)
Gross Margin QoQ = -9999 % (prev -9999 %)
Tobins Q-Ratio = 0.79 (Enterprise Value 336.5m / Total Assets 424.0m)
Interest Expense / Debt = 6.34% (Interest Expense 1.41m / Debt 22.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -178.6m (EBIT -226.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.42 (Total Current Assets 312.4m / Total Current Liabilities 37.1m)
Debt / Equity = 0.06 (Debt 22.3m / totalStockholderEquity, last quarter 369.0m)
Debt / EBITDA = 0.12 (negative EBITDA) (Net Debt -26.3m / EBITDA -226.8m)
Debt / FCF = 0.14 (negative FCF - burning cash) (Net Debt -26.3m / FCF TTM -185.1m)
Total Stockholder Equity = 442.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -49.34% (Net Income -209.2m / Total Assets 424.0m)
RoE = -47.27% (Net Income TTM -209.2m / Total Stockholder Equity 442.6m)
RoCE = -48.64% (EBIT -226.1m / Capital Employed (Equity 442.6m + L.T.Debt 22.3m))
RoIC = -40.36% (negative operating profit) (NOPAT -178.6m / Invested Capital 442.6m)
WACC = 10.46% (E(619.3m)/V(641.6m) * Re(10.66%) + D(22.3m)/V(641.6m) * Rd(6.34%) * (1-Tc(0.21)))
Discount Rate = 10.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 19.76%
Fair Price DCF = unknown (Cash Flow -185.1m)
EPS Correlation: -13.55 | EPS CAGR: -24.91% | SUE: 0.0 | # QB: 0
Revenue Correlation: -24.20 | Revenue CAGR: -0.58% | SUE: -0.08 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.93 | Chg30d=+0.037 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-3.48 | Chg30d=+0.322 | Revisions Net=+5 | Growth EPS=-6.8% | Growth Revenue=-40.2%
Additional Sources for FDMT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle